Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) was able to establish a partnership deal with Novartis AG (NVS) to develop a molecular glue degrader [MGD] drug known as MRT-6160 for the treatment of ...

1km from Glenhaven Primary School First listed on 24 October, this property has been on Domain for less than a day (last updated on 24 October). It was last sold in 2022.

DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

Summit Therapeutics stock shot higher this September in response to outstanding clinical-trial results. The company's lead candidate is a cancer therapy that's already approved in China.

Viking Therapeutics Inc (NASDAQ:VKTX) reported positive data from four clinical programs, including VK2735 for obesity and VK2809 for NASH and fibrosis. The Phase II VENTURE trial for VK2735 ...

Think of a full-height door as the minimalist's dream—its unbroken silhouette is not just visually striking but also cleverly designed to be flush with walls and ceilings, rendering it almost ...

End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH ...

Seaport Therapeutics, the startup launched earlier this year by the team behind Karuna Therapeutics, has raised another $225 million just six months after its most recent fundraising round.